Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|10057||ETCTN||A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|10005||ETCTN||A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10009||ETCTN||A Phase 1b study of the anti-PD1 antibody Pembrolizumab in combination with the histone deacetylase inhibitor; Entinostat for treatment of patients with myelodysplastic syndromes after DNA methyltransferase inhibitor therapy failure||Adult CIRB - Early Phase Emphasis||Available to Open|
|10010||ETCTN||A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent; Persistent or Metastatic Cervical Cancer||Adult CIRB - Early Phase Emphasis||Completed|
|10013||ETCTN||Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)||Adult CIRB - Early Phase Emphasis||Available to Open|
|10014||ETCTN||A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies||Adult CIRB - Early Phase Emphasis||Available to Open|
|10015||ETCTN||A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10017||ETCTN||A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer||Adult CIRB - Early Phase Emphasis||Completed|
|10020||ETCTN||A Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|10021||ETCTN||A Phase 2 Study of MEDI4736(durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC||Adult CIRB - Early Phase Emphasis||Available to Open|